Amgen and Immatics Biotechnologies GmbH announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers. The collaboration will combine Immatics' XPRESIDENT® target discovery and T-cell receptor (TCR) capabilities with Amgen's validated Bispecific T-cell Engager (BiTE®) technology with the aim of creating novel oncology drugs. Under the terms of the agreement, Immatics will receive an upfront fee of $30 million and is eligible to receive over $500 million in development, regulatory and commercial milestone payments for each program and tiered royalties up to a double-digit percentage of net sales.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.55 USD | -0.08% |
|
+2.45% | +19.18% |
15/05 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
14/05 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.18% | 1.29B | |
+20.17% | 126B | |
+24.67% | 118B | |
+25.04% | 27.87B | |
-17.74% | 20.95B | |
-15.17% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- IMTX Stock
- News Immatics N.V.
- Amgen and Immatics Biotechnologies GmbH Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies